Press Conference Schedule

Tuesday, August 2 and Wednesday, August 3
Rooms 121A and 121B
Pennsylvania Convention Center
Philadelphia

TUESDAY, AUGUST 2

Abbott Diagnostics

9–9:45 a.m.
Room 121A

The Future of Diagnostics

Join Abbott’s Brian Blaser, Executive Vice President of Diagnostics Products; Dennis Gilbert, Vice President of Diagnostics Research and Development; and Sharon Bracken, President for Point of Care, for a first look at the company’s next-generation diagnostic systems spanning immunoassay, clinical chemistry, point of care, hematology, molecular and blood screening. Learn how Abbott developed its unified suite of instruments to help address several challenges and pressures the healthcare system faces by leveraging extensive insights from clinicians, scientists, lab technicians, and C-suite executives from around the world. Coffee and light refreshments will be served.

Sysmex

10–10:45 a.m.
Room 121A

Aalto Bio Reagents

10–10:45 a.m.
Room 121B

AWEsome Numbers

11–11:45 a.m.
Room 121A

“Does your medical laboratory need M.O.R.E. Quality™?” That is the question asked and answered by Zoe Brooks, visionary, entrepreneur and CEO of AWEsome Numbers Inc. That leads to: “What lies beyond six sigma?” and “How would it impact patients harmed and clinical costs if laboratories had an automated process to maintain medically-acceptable risk and cost?”

Brooks’ process of Mathematically-OptimiZed Risk Evaluation™ upgrades existing Statistical QC and sigma concepts. M.O.R.E. Quality™ automates the specific directions from ISO, IQCP, CLSI EP 23-A. This paradigm shift in mindset, education and software holds promise to reduce numerical laboratory errors by 50%.

Advanced Instruments

11–11:45 a.m.
Room 121B

Roche Diagnostics

12–12:45 p.m.
Room 121A

Roche Diagnostics Media Briefing and Q&A

Lunch provided: Create-A-Sandwich

Media are invited to join Roland Diggelmann, Chief Executive Officer Roche Diagnostics and Jack Phillips, President and CEO Roche Diagnostics Corporation North America, for a media briefing and Q&A session to discuss Roche Diagnostics’ performance and its future strategy. Lunch will be provided.

Oncolab

1–1:45 p.m.
Room 121A

NVIGEN

2–2:45 p.m.
Room 121A

Go Beyond Ordinary – Leverage the Richest Nanoparticle Chemistry and Engineering Platform for Highly Efficient Magnetic Separation

NVIGEN designs and engineers functional nanoparticles and surface conjugations.  Our MagVigen™ magnetic nanoparticles are engineered ideal for magnetic separation. They are fast yet gentle, causing minimal disruption to your target biomolecules - proteins, nucleic acids, or cells - permitting the isolation and preservation of labile compositions and conformations that might otherwise being interfered. Key applications include: protein purification, immuno-diagnostics, DNA size separation, sequence specific DNA capture, cfDNA extraction, circulating tumor cell isolation, and T cell activation and expansion. 

For more information, call 408-970-9988, visit www.nvigen.com, email info@nvigen.com, or stop by Booth #1562.

TELCOR

2–2:45 p.m.
Room 121B

Make Inspections Productive and Efficient: TELCOR Releases Innovative eLearning Interface

TELCOR, the leading vendor truly focused on point of care testing (POCT) middleware innovations, has introduced the first interface that seamlessly updates operator demographic information and competency completion information directly from a facility’s LMS/HRIS to its POCT middleware solution.  CAP/CMS/JCAHO inspections become more productive and efficient because operator and competency record updates along with the count of tests performed by each operator are combined into one system. Automatically completing competency requirements allows seamless continuity of patient care when sending operator updates to POCT devices for those who completed their competency requirements and oversight of those who have not.

Mayo Medical Laboratories

4–4:45 p.m.
Room 121B

Mayo Clinic and Zora Biosciences Launch New Blood Test—First in U.S.—that Assesses Risk of Heart Attack Using Plasma Ceramides

Mayo Medical Laboratories, the clinical and reference laboratory of Mayo Clinic, and Zora Biosciences Oy, a diagnostics discovery company specializing in cardiovascular disease, have successfully developed a new method that can aid in predicting risk of imminent adverse cardiovascular events in patients. The new test will help clinicians identify at-risk individuals by measuring blood concentrations of ceramides, a class of lipids that add predictive power to current biomarkers. Mayo Medical Laboratories is currently the only laboratory in the U.S. to offer this test.

 

WEDNESDAY, AUGUST 3

Instrumentation Laboratory

9–9:45 a.m.
Room 121A

New Innovations in Hemostasis Automation – Enhancing Lab Efficiency and Reducing Variability in Patient Care

Speaker:  Giovanni Russi, Vice President, Worldwide Marketing and Service, IL

Instrumentation Laboratory, the global market leader in Hemostasis IVD, is passionate about innovation. This year, we are introducing several significant products, including new ACL TOP® Family 50 Series Testing Systems, with advanced automation for routine and specialty testing.  Completely standardized, each model integrates pre-analytical sample integrity checks, advanced quality management and lab accreditation tools ─ a true breakthrough.  And, new HemoHub™ Intelligent Data Manager offers unmatched operational performance and clinical-decision support from a single workstation, while HemoCell™ Specialized Lab Automation, the first automated workcell solution designed specifically for Hemostasis testing, optimizes workflow.  Also featured are several novel reagents including HemosIL® Readiplastin®, our liquid PT assay, delivering excellent performance with ready-to-use convenience.  Every IL product helps improve lab efficiency and ensure quality patient care.  Come learn more about IL and our innovative new products!

bioMérieux

9–9:45 a.m.
Room 121B

Unique Kinetics of Procalcitonin Levels Over Time Provide Strong Indication of Survival and Enable Physicians to Make More Confident Decisions

The FDA cleared the VIDAS® B•R•A•H•M•S PCT™ (Procalcitonin) assay to measure the change in PCT levels over time. Based on a recent study, patients’ whose PCT levels did not drop by more than 80% from days 1-4 had a two-fold increase in mortality. This new use will enable doctors to adjust medical care for these high-risk patients. PCT is a biomarker of severe bacterial infection and is one of the earliest indicators of likely sepsis. This new use of PCT adds to its clinical value by assisting in both the initial diagnosis and the ongoing assessment of sepsis patients.

Bio-Rad Laboratories

10–10:45 a.m.
Room 121A

Bio-Rad Takes Molecular Diagnostics Testing to a New Level

Members of the media won’t want to miss Bio-Rad’s unveiling of several new molecular quality controls, among which is the first molecular control to be issued a de novo clearance from the FDA. Join Max Williams, Global Marketing Director, Bio-Rad, Rochelle Stahl, Product Manager, Molecular Diagnostic Controls, Bio-Rad and Jamie Platt, PhD, CGMBS, MB(ASCP), President and Founder of BRIDGenomics to learn about how these new controls conveniently monitor the analytical process including sample extraction, amplification and detection. An exciting new video will be debuted highlighting Bio-Rad’s new offerings for molecular diagnostics testing. Light refreshments will be served.  

Tecan

10–10:45 a.m.
Room 121B

Tecan AACC 2016 Press Conference: Empowering Diagnostic Workflows

At the AACC 2016 conference, Tecan will hold a press conference hosted by CEO Dr. David Martyr, and Dr. Achim von Leoprechting, Executive Vice President, Head of Tecan Partnering. The press conference will feature new automation solutions for routine diagnostics and key strengths at Tecan – the capacity to support customers as they move from research to clinical applications. www.tecan.com/aacc2016

The Technology Partnership

11–11:45 a.m.
Room 121A

Translating Biological Assays into Market-Ready Products That Deliver ‘Sample to Answer’ from 15 Minutes

Point-of-care diagnostic providers often face challenges when transferring their biology into an instrument for use in diagnostics or research. This press conference will explore these problems, and discuss how they can be addressed by The Technology Partnership’s (TTP) Desktop Biology™, a new service that provides an accessible and rapid route to market for companies who want to translate complex biological assays into low-cost, disposable consumables. Find out from TTP experts the unique benefits and applications of the new service, and how it will impact upon the future landscape of this emerging market.

Proteome Tech

11–11:45 a.m.
Room 121B

Accel Biotech

1–1:45 p.m.
Room 121A

During this press conference, Accel will detail joining forces with Ximedica, a leading full service medical technologies development firm, to expand our existing portfolios while continuing to focus on IVD technology expertise. Accel’s operation in Silicon Valley complements Ximedica’s base in Rhode Island along with offices in Hong Kong and Minnesota. The union expands Ximedica’s capability into IVD instrumentation and companion disposables, while Ximedica brings a mature quality system, regulatory consultation, strong human factors and industrial design capability including recently added Bridge Design of San Francisco. Executives from Accel Biotech and Ximedica will present the briefing followed by a question and answer session.

Diazyme

2–2:45 p.m.
Room 121B

Diazyme Laboratories Partners with GlycoMark to Launch FIRST Comprehensive Panel for Diabetes Management

Panel features GlycoMark—The ONLY Blood Test that Specifically Indicates Recent Hyperglycemia

Recent studies have clearly linked hyperglycemic excursions to increased incidence of cardiovascular disease, neuropathy, tissue damage and death, highlighting the need for additional glucose testing beyond the traditional HbA1c for patients with diabetes. Measuring 1,5-anhydroglucitol (1,5-AG), GlycoMark is a specific indicator of recent hyperglycemia—the culprit in tissue damage caused by diabetes. Join Diazyme’s Managing Director Dr. Chong Yuan, GlycoMark’s President Larry Thomas and Business Development Executive Kelly McHugh, and leading endocrinologist Michael Shanik, MD to discuss the utility of GlycoMark and its impact on managing patients with diabetes.

SNIBE (Shenzhen New Industries Biomedical Engineering)

3–3:45 p.m.
Room 121A

17-OH Progesterone, Clinical Value, and Automation

Snibe, a professional bio-medical company specialized in in-vitro diagnosis products, applies the most advanced magnetic microbeads as key separation material in CLIA system and synthesized small-molecule inorganic compound as marker, replacing traditional enzyme.

17-OH progesterone, which is a hormone produced by the adrenal glands. The body uses 17-OH progesterone and certain enzymes to make cortisol, a hormone involved in stress and the fight-or-flight response. When the body doesn’t make enough of these enzymes, it can’t create enough cortisol. This causes 17-OH progesterone to build up in the blood. Increased levels of 17-OH progesterone in the blood can indicate a condition called congenital adrenal hyperplasia.